Next Article in Journal
Effects of an Adaptogenic Extract on Electrical Activity of the Brain in Elderly Subjects with Mild Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled, Two-Armed Cross-Over Study
Previous Article in Journal
Fatty Acid Amides Synthesized from Andiroba Oil (Carapa guianensis Aublet.) Exhibit Anticonvulsant Action with Modulation on GABA-A Receptor in Mice: A Putative Therapeutic Option
Open AccessArticle

Preparation, Characterization, and Evaluation of Cisplatin-Loaded Polybutylcyanoacrylate Nanoparticles with Improved In Vitro and In Vivo Anticancer Activities

1
Department of Pilot Nanobiotechnology, Pasteur Institute of Iran, Tehran 1316943551, Iran
2
Department of Chemical Engineering, Shahrood Branch, Islamic Azad University, Shahrood 36155-163, Iran
3
School of Mechanical, Medical and Process Engineering, Queensland University of Technology (QUT), Brisbane, Queensland 4000, Australia
4
School of Pharmacy, The University of Queensland, Woolloongabba 4102, Australia
5
Department of Microbiology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan 7717933777, Iran
*
Authors to whom correspondence should be addressed.
Pharmaceuticals 2020, 13(3), 44; https://doi.org/10.3390/ph13030044
Received: 25 February 2020 / Revised: 5 March 2020 / Accepted: 7 March 2020 / Published: 11 March 2020
(This article belongs to the Section Biopharmaceuticals)
This study aimed to evaluate the therapeutic efficacy of the cisplatin encapsulated into polybutylcyanoacrylate (PBCA) nanoparticles for the treatment of kidney cancer. The nanoformulation was successfully developed using the miniemulsion polymerization method and characterized in terms of size, size distribution, drug loading and encapsulation efficiencies, drug release behavior, in vitro cytotoxicity effects, in vivo toxicity, and therapeutic effects. Cisplatin-loaded PBCA nanoparticles were confirmed to be in nanoscale with the drug entrapment efficiency of 23% and controlled drug release profile, in which only 9% of the loaded drug was released after 48 h. The nanoparticles caused an increase in the cytotoxicity effects of cisplatin against renal cell adenocarcinoma cells (ACHN) (2.3-fold) and considerably decreased blood urea nitrogen and creatinine concentrations when compared to the standard cisplatin (1.6-fold and 1.5-fold, respectively). The nanoformulation also caused an increase in the therapeutic effects of cisplatin by 1.8-fold, in which a reduction in the mean tumor size was seen (3.5 mm vs. 6.5 mm) when compared to the standard cisplatin receiver rats. Overall, cisplatin-loaded PBCA nanoparticles can be considered as a promising drug candidate for the treatment of kidney cancer due to its potency to reduce the side effects of cisplatin and its toxicity and therapeutic effects on cancer-bearing Wistar rats. View Full-Text
Keywords: cisplatin; cytotoxicity; drug delivery; kidney cancer; PBCA nanoparticles cisplatin; cytotoxicity; drug delivery; kidney cancer; PBCA nanoparticles
Show Figures

Figure 1

MDPI and ACS Style

Ghaferi, M.; Amari, S.; Vivek Mohrir, B.; Raza, A.; Ebrahimi Shahmabadi, H.; Alavi, S.E. Preparation, Characterization, and Evaluation of Cisplatin-Loaded Polybutylcyanoacrylate Nanoparticles with Improved In Vitro and In Vivo Anticancer Activities. Pharmaceuticals 2020, 13, 44.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop